Price Alert

Lyra Therapeutics Inc. (LYRA)

NASDAQ: LYRA · Real-Time Price · USD

7.02

-0.08 (-1.13%)

At close: Aug 15, 2025, 12:48 PM

-1.13% (1D)

Bid	6.83
Market Cap	11.54M
Revenue (ttm)	1.19M
Net Income (ttm)	-79.53M
EPS (ttm)	-28.99
PE Ratio (ttm)	-0.24
Forward PE	-0.86
Analyst	Hold

Ask	7.17
Volume	5,440
Avg. Volume (20D)	665,204
Open	6.92
Previous Close	7.10
Day's Range	6.81 - 7.19
52-Week Range	3.81 - 37.50
Beta	0.16

About LYRA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol LYRA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for LYRA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Lyra Therapeutics has released their quartely earnings on Aug 12, 2025:

Revenue of $183K exceeds estimates by $14.25K, with -69.40% YoY decline.

EPS of -5.51 misses estimates by -0.33, with 85.01% YoY growth.

Next Earnings Release

Lyra Therapeutics Inc. is scheduled to release its earnings on Nov 11, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-31.91%

Lyra Therapeutics shares are trading lower after t... Unlock content with Pro Subscription

2 months ago

+310.75%

Lyra Therapeutics shares are trading higher after the company announced its ENLIGHTEN 2 Phase 3 trial of LYR-210 met its primary endpoint.

News

3 days ago · zacks.com

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates

Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $5.51 per share versus the Zacks Consensus Estimate of a loss of $5.79. This compares to a loss of $14.5 per share a year ago.

2 months ago · seekingalpha.com

Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst

Lyra Therapeutics has lost >90% of its value since announcing the failed ENLIGHTEN-1 trial, despite the recent announcement of a clearly positive ENLIGHTEN-2. Considering a clearly positive phase 3, s...

2 months ago · zacks.com

Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why

Lyra Therapeutics (LYRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago · zacks.com

Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success

LYRA skyrockets 356% after its lead nasal implant, LYR-210, meets key goals in a pivotal phase III chronic rhinosinusitis study.

2 months ago · finbold.com

This penny stock just spiked 550% in a day; Time to buy?

Lyra Therapeutics (NASDAQ: LYRA) ‘s shares surged 550% in pre-market trading on Monday following a breakthrough in its drug trials.

2 months ago · benzinga.com

Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?

Lyra Therapeutics, Inc. LYRA released results on Monday from the ENLIGHTEN 2 Phase 3 trial of LYR-210 in adult patients with Chronic Rhinosinusitis (CRS).